Trevi Therapeutics (TRVI) Tops Q1 EPS by 1c
Tweet
Share
E-mailGet Alerts TRVI Hot Sheet
Join SI Premium – FREE
Trevi Therapeutics (NASDAQ: TRVI) reported Q1 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- William Blair Upgrades Backblaze Inc (BLZE) to Market Perform
- Ennis (EBF) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
